Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
- Status
- TERMINATED
- Phase
- PHASE2
Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease
- Status
- UNKNOWN
- Phase
- PHASE2
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
- Status
- COMPLETED
- Phase
- PHASE2
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Response of Dasatinib to Treat Mastocytosis
- Status
- UNKNOWN
- Phase
- PHASE2
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
- Status
- COMPLETED
- Phase
- PHASE1
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE2
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
- Status
- TERMINATED
- Phase
- PHASE1
Study of Erlotinib in Combination With Dasatinib
- Status
- COMPLETED
- Phase
- PHASE1
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
- Status
- COMPLETED
- Phase
- PHASE2